"Why won't my insurance pay for this?" is one of the most common questions we hear, usually asked with real frustration behind it. It's a fair frustration. Here's the honest explanation, and what patients actually do about it.
Why U.S. Insurers Classify These Treatments the Way They Do
Most U.S. insurance plans place regenerative medicine in the "experimental" or "elective" category. That classification is largely a regulatory and actuarial one, tied to how slowly coverage policy catches up with newer treatment categories, rather than a direct statement about whether a given treatment can help a given patient. The practical result is the same either way: patients are left paying out-of-pocket.
What This Means for the U.S. Out-of-Pocket Price
Because these treatments sit outside standard coverage, U.S. clinics price them to reflect full facility overhead, administrative cost, and insurance-adjacent billing infrastructure that self-pay patients end up absorbing directly. This is a major part of why comprehensive regenerative care plans in the U.S. commonly run $8,000–$15,000 for a single joint.
What Options Actually Exist
- HSA or FSA funds: Many patients are able to apply these toward treatment, but eligibility varies by plan. We're not a tax or insurance advisor, so we always recommend confirming directly with your plan administrator.
- Payment plans through your own bank or provider: Some patients choose to finance care independently, the same way they would for any major out-of-pocket expense.
- Self-pay medical travel: A direct-to-patient model, without U.S. facility overhead, is the approach we've built our own pricing around.
"A lower price doesn't mean lower quality. It's the result of a streamlined, direct-to-patient healthcare model."
Why the Math Changes Across the Border
At Altevia Health, our starting packages are $3,750 USD, generally 60–70% below comparable out-of-pocket care in the U.S. This isn't a discount on quality; it reflects lower real estate and administrative costs, a direct-to-patient billing model, and working directly with certified laboratories rather than through layers of U.S. intermediaries.
Related reading: The full breakdown of U.S. vs. Mexico pricing · What happens if you're not a candidate
Frequently Asked Questions
Most U.S. insurers classify these treatments as experimental or elective, which places them outside standard coverage policies, regardless of individual clinical results.
Many patients are able to, but eligibility depends on your specific plan. We recommend checking directly with your plan administrator before your visit.
Often, yes. A direct-to-patient, self-pay model without U.S. facility overhead is a major reason our starting packages run 60-70% below typical U.S. out-of-pocket pricing for comparable care.
See transparent pricing for your case.
Start with our short intake form. Our team will walk you through exact package pricing before you decide anything.
Request an Evaluation